The global blood screening market is anticipated to grow at a CAGR of 6.9% during the forecast period (2021-2027). The rising prevalence of COVID-19 cases, rising testing for the disease, increasing awareness for the treatment, and rising FDA approvals, are driving the blood screening market during the forecast period. According to the Worldometers, as of 10th May 2021, around 159 million COVID-19 cases were reported that have been tested positive. In March 2020, Becton, Dickson, and Co., a medical technology company, and BioMedomics, a North Carolina-based clinical diagnosis company, had launched the FDA-approved point-of-care test to detect antibodies in blood to confirm that the current or past exposure of COVID-19 in 15 minutes.
To Request a Sample of our Report on Blood Screening Market: https://www.omrglobal.com/request-sample/blood-screening-market
In July 2020, Becton, Dickinson, and Co. had announced that the US FDA approved an Emergency Usage Authorization for a rapid, point-of-care SARS-CoV-2 diagnostic test for use with the BD VeritorTM Plus System, which is widely available. The introduction of this new assay, which provides results in 15 minutes on a simple-to-use, highly portable instrument, is vital for increasing access to COVID-19 diagnostics owing to it allows for real-time results and decision-making while the patient is still in the hospital. Apart from it, in February 2021, Siemens Healthcare GmbH had announced that the laboratory test for the SARV-CoV-2 Antigen assay of the company got a CE mark and has submitted the test to the US FDA for emergency use authorization (EUA). Thus, the various technological advancements in the tests by key players, rising FDA approvals to detect antibodies in the blood, new blood screening devices, and among others, are the factors that are driving the growth of the market during the forecast period.
Market Coverage
· The market number available for – 2020-2027
· Base year- 2020
· Forecast period- 2021-2027
Segment Covered-
· By Screening Technology
· By Products
· By End-Users
Regions Covered-
· North America
· Europe
· Asia-Pacific
· Rest of the World
· Competitive Landscape- Abbott Laboratories, Becton Dickinson and Co., BioAim Scientific Inc, Bio-Rad Laboratories, Inc, Danaher Corporation, Demeditec Diagnostics GmbH, F. Hoffmann-La Roche Ltd., Grifols, Siemens Healthcare GmbH, Immuno-Biological Laboratories, Inc., among others.
Recent Activities by the Key Players in Global Blood Screening Market
· In April 2020, Abbott Laboratories had announced the launch of another COVID-19 test, which is a lab-based serology blood test for detection of antibody, IgG, for defining the COVID-19 in the person’s body. This test tells that if a person has been previously infected and how long antibodies stay in the body.
· In June 2019, Abbott Laboratories had got the US FDA approval for its Alinity line of laboratory diagnostics hardware designed to blood screen and plasma donation for potential containment. This was designed for a smaller space, also can perform 600 tests in an hour.
(Get 15% Discount on Buying this Report)
A full Report of Blood Screening Market is Available at: https://www.omrglobal.com/industry-reports/blood-screening-market
Global Blood Screening Market Report Segment
By Screening Technology
· Nucleic Acid Amplification Test
· Western Blotting
· Enzyme-Linked Immunosorbent Assay
· PCR-RNA
By Products
· Testing Instruments
· Reagents
· By End-Users
· Blood Banks
· Hospitals
· Laboratories
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
